Novo Nordisk's weight-loss medication, Wegovy, has received clearance from the National Institute for Health and Care Excellence (NICE) for use in patients suffering from heart disease alongside obesity. This landmark decision is expected to considerably broaden the drug's availability within the UK, potentially offering a new treatment option for an estimated 1.2 million individuals who meet the updated criteria.
Wegovy, which contains the active ingredient semaglutide, works by mimicking a hormone that targets areas of the brain involved in appetite regulation. It was already accessible on the NHS for weight management in certain patients who met specific criteria, typically those with a Body Mass Index (BMI) of 30 or more, or 27.5 for some ethnic groups, and at least one weight-related comorbidity. The latest recommendation from NICE extends this access to a crucial new patient group, focusing on those with established cardiovascular disease.
The expanded approval is underpinned by clinical trial data, specifically the SELECT trial, which demonstrated that semaglutide not only aids in significant weight loss but also reduces the risk of major adverse cardiovascular events, such as heart attack and stroke, in individuals with obesity and existing heart disease. This evidence highlights the drug's potential beyond simple weight reduction, positioning it as a tool for improving long-term cardiovascular health outcomes.
For patients to access Wegovy through the NHS, they must typically be referred to specialist weight management services. These services assess individual suitability for the medication, monitor progress, and provide comprehensive support, including lifestyle interventions. The introduction of Wegovy for this expanded indication is likely to place additional demands on these specialist services, which are already under pressure.
Obesity remains a significant public health challenge in the UK, with statistics indicating that approximately one in four adults are living with obesity. This condition is a major risk factor for numerous health problems, including type 2 diabetes, certain cancers, and cardiovascular diseases. The availability of effective treatments like Wegovy, especially for those at high risk of heart-related complications, represents an important step in managing these widespread health issues. Patients considering this treatment should always consult their GP for advice.